Laboratorios Farmaceuticos Rovi, S.A. (BME: ROVI)
Health Care · Pharmaceuticals · ES
€60.50
+1.09% today · +3.8% 1Y
Laboratorios Farmaceuticos Rovi, S.A. (BME: ROVI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.61B and employs 2,470 people.
Over the last twelve months the share price has gained 3.8%, trading between 53.10 and 86.70.
Tweenvest scores Laboratorios Farmaceuticos Rovi, S.A. across four factors: quality 77/100, value 59/100, growth 55/100, dividend 60/100. Its strongest factor is quality.
ROVI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.61B
- Revenue (TTM)
- $883.19M
- P/E
- 16.71
- EPS
- 3.62
- Dividend yield
- 1.60%
- Beta (5Y)
- 0.23
- 52-week high
- €86.70
- 52-week low
- €53.10
- Avg volume (3M)
- —
- Shares outstanding
- 51.14M
- Employees
- 2,470
- Next earnings
- —
About Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses on researching, developing, manufacturing, and commercializing medicinal products. Its operations span Spain, the European Union, OECD nations, and global markets. The company also markets certain products under license from other manufacturers. Its primary pharmaceutical portfolio includes Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins for preventing and treating venous thromboembolic conditions. Neparvis targets symptomatic chronic heart failure with reduced ejection in adult patients. For managing hypercholesterolemia, Rovi offers Absorcol, Vytorin, and Orvatez. Respiratory diseases like chronic obstructive pulmonary disease are treated with long-acting bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is available for men with benign prostatic hyperplasia (BPH) experiencing moderate to severe storage and voiding symptoms who have not adequately responded to monotherapy. Additionally, Medikinet and Medicebrán are used for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Beyond pharmaceuticals, Rovi provides various hospital solutions for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventions, Multihance and Prohance for MRI, and Sonovue for ultrasounds. It also supplies contrast injection systems such as EmpowerCTA+, EmpowerMR, and CT Exprès, along with compatible disposable materials. The company's offerings extend to over-the-counter pharmaceuticals and contract manufacturing services for other firms, producing a range of dosage forms like prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi serves a broad client base, including pharmaceutical wholesalers, medical professionals, nurses, pharmacists, and individual patients. Notably, Rovi has partnered with Moderna, Inc. for the production of an mRNA COVID-19 vaccine candidate. Established in 1946, the company is headquartered in Madrid, Spain, and operates as a subsidiary of Norbel Inversiones, S.L.
- ISIN
- ES0157261019
- Founded
- 1946
- Listed since
- Dec 5, 2007
- Exchange
- Bolsas y Mercados Espanoles
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.